Boost to melanoma support in WA
31 January 2020
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
One Australian dies from melanoma every five hours and WA is second only to QLD in terms of melanoma incidence across Australia.
Chairman of melanomaWA, Martin Slabbert, said the merger with Melanoma Institute Australia was exciting and would have widespread benefits for the entire West Australian community.
‘The two highly respected organisations will be working together on a regional and national level regarding awareness, education, support, and research,’ Mr Slabbert said.
‘Importantly, the alignment will also provide local, regional, and remote melanoma patients with greater access to medical specialists through Melanoma Institute Australia’s network. This coordinated approach has been well received by patients connected with melanomaWA.’
CEO of Melanoma Institute Australia, Matthew Browne, said the merger would ensure increased resources dedicated to reducing the impact of melanoma on the community in WA.
‘Melanoma Institute Australia is delighted to be merging with melanomaWA,’ Mr Browne said. ‘Melanoma is, unfortunately, Australia’s national cancer and accordingly combining organisations from west coast and the east coast gives us all the best chance of fighting this disease.
‘Joining two strong melanoma organisations immediately brings increased resources and services to melanoma patients as well as a broader coordinated reach in raising awareness about early detection and prevention strategies including sun safety.’
The first fundraising and awareness event of the combined entity will be Melanoma March which will be held in Bunbury on 15th March and at Perth’s Cottesloe Beach on 29th March. Funds raised from the family-friendly Melanoma March events will support melanoma research to pave the way for new and life-saving treatments.
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.
MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.
MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.
Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.
New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.
However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.
Thank you to everyone involved in making Melanoma March 2016 a huge success
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.